Paraneoplastik Romatolojik Sendromlar
Özet
Paraneoplastik romatolojik sendromlar, malignitenin neden olduğu, tümör kitlesi veya metastazlar ile doğrudan ilişkili olmayan, tümör kaynaklı çözünür faktörlerin ya da immün mekanizmaların aracılık ettiği nadir ve heterojen bir hastalık grubudur. Genellikle altta yatan maligniteden uzak bölgelerde gelişen bu sendromlar eklemleri, fasyaları, kasları, damarları ve kemikleri etkileyerek çeşitli kas-iskelet sistemi semptomlarına yol açar. Primer neoplazm tanısıyla eş zamanlı görülebildiği gibi kanserin klinik başlangıcından yaklaşık iki yıl öncesinde de ortaya çıkabilirler. En sık rastlanan türleri arasında tekrarlayıcı seronegatif pitting ödemli simetrik sinovit (RS3PE), paraneoplastik poliartrit, palmar fasiit, hipertrofik osteoartropati, kanser ilişkili miyozit ve paraneoplastik vaskülitler yer alır. Bu sendromların ayırt edici bir özelliği, standart glukokortikoidlere ve hastalık modifiye edici anti-romatizmal ilaçlara zayıf veya minimal yanıt vermeleridir. Klinik seyirleri çoğunlukla primer tümörün seyrine paralel olup altta yatan malignitenin cerrahi rezeksiyon veya kemoterapi ile etkin şekilde tedavi edilmesi, romatizmal semptomların ve bulguların gerilemesini sağlar. Bu nedenle, tedavilere dirençli veya atipik seyreden romatolojik hastalıkların paraneoplastik sendrom olabileceğini akılda tutmak, gizli tümörlerin erken teşhisi için son derece kritiktir.
Paraneoplastic rheumatological syndromes constitute a rare and heterogeneous group of musculoskeletal disorders induced by underlying malignancies, which are not directly related to the tumor mass or metastases but are instead mediated by tumor-secreted soluble factors or immune responses. These syndromes commonly develop at sites distant from the primary tumor, causing clinical symptoms in the joints, fascia, muscles, blood vessels, and bones. They may manifest concurrently with the diagnosis of the primary neoplasm or precede its discovery by up to two years. The most frequently observed manifestations include remitting seronegative symmetrical synovitis with pitting edema (RS3PE), paraneoplastic polyarthritis, palmar fasciitis, hypertrophic osteoarthropathy, cancer-associated myositis, and paraneoplastic vasculitis. A key clinical characteristic of these paraneoplastic conditions is their poor or minimal response to conventional glucocorticoids and disease-modifying antirheumatic drugs. Their clinical course typically parallels that of the primary tumor; consequently, successful treatment of the underlying cancer through surgical resection or chemotherapy frequently results in the regression or resolution of the rheumatological symptoms. Awareness of these atypical and treatment-resistant presentations is therefore vital for clinicians to ensure the early detection and management of hidden malignancies.
Referanslar
de Figueiredo IR, Alves RV, Sara SG, et al. Rheumatologic Diseases as Paraneoplastic Syndromes-A Paradigmatic Case. Journal of Rheumatic Diseases and Treatment 2018;4:067. doi: 10.23937/2469-5726/1510067
Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Current Opinion in Rheumatology 2013;25(1):44-49. doi:10.1097/BOR.0b013e328359e780
Fam AG. Paraneoplastic rheumatic syndromes. Bailliere's best practice & research. Clinical rheumatology 2000;14(3):515–533. doi:10.1053/berh.2000.0091
Bhakta BB, Pease CT. Late-onset rheumatoid arthritis: is pitting oedema of the hands at onset a good prognostic indicator? British journal of rheumatology 1997;36:214-9. doi: 10.1093/rheumatology/36.2.214
Schaeverbeke T, Fatout E, Marce S, et al. Remitting seronegative symmetrical synovitis with pitting oedema: diseases or syndrome? Annals of the Rheumatic Diseases 1995; 54: 681-684
Finnell JA, Cuesta IA. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a review of the literature and a report of three cases. The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons 2000;39:189-93. doi: 10.1016/s1067-2516(00)80021-6
Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Seminars in Arthritis and Rheumatism 2010; 40:89–94. doi:10.1016/j.semarthrit.2008.11.006
Li H, Altman RD, Yao Q. RS3PE: Clinical and research development. Current rheumatology reports 2015;17:49. doi: 10.1007/s11926-015-0525-0.
Gokcen N, kozanoglu E. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Cukurova Medical Journal 2017;42(1):147-154. doi:10.17826/cutf.280187
Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Modern Rheumatology 2012; 22:584–588. doi:10.1007/s10165-011-0556-y
Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clinical and experimental rheumatology 1999;17:741-4.
Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nature reviews. Rheumatology 2014;10(11):662–670. doi:10.1038/nrrheum.2014.138
Sheon RP, Kirsner AB, Tangsintanapas P, et al. Malignancy in rheumatic disease: interrelationships. Journal of the American Geriatrics Society 1977;25(1):20-27. doi:10.1111/j.1532-5415.1977.tb00918.x
Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. International journal of rheumatic diseases 2014;17:640. doi:10.1111/1756-185X.12277
Parperis K, Constantinidou A, Panos G. Paraneoplastic Arthritides: Insights to Pathogenesis, Diagnostic Approach, and Treatment. Journal of Clinical Rheumatology 2021;27(8):e505-e509. doi:10.1097/RHU.0000000000001202
Schultz H, Krenn V, Tony HP. Oligoarthritis mediated by tumor-specific T lymphocytes in renal-cell carcinoma. The New England journal of medicine 1999;341(4): 290-1. doi:10.1056/NEJM199907223410415
Alexandroff AB, Hazleman BL, Matthewson M, et al. Woody hands. Lancet 2003;361(9366):1344. doi:10.1016/s0140-6736(03)13082-6
Manger B, Schett G. Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases. Seminars in Arthritis and Rheumatism 2014:44:105. doi:10.1016/j.semarthrit.2014.03.005
Manger B, Schett G. Rheumatic paraneoplastic syndromes-Links between malignancy and autoimmunity. In: Firestein GS, Budd RC, Gabriel SE, et al. (Eds.), Kelley and Freinstein’s Textbook of Rheumatology. (11th ed., pp 2161-66). Philadelphia: Elsevier.
Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Archives of internal medicine 1989;149(1):105-109
Mork C, Asker CL, Salerud EG, et al. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. The Journal of investigative dermatology 2000;114(4):643-646. doi:10.1046/j.1523-1747.2000.00944.x
Cohen JS. Erythromelalgia: new theories and new therapies. Journal of the American Academy of Dermatology 2000;43(5 Pt 1):841-847. doi:10.1067/mjd.2000.109301
Malignancy and rheumatic disorders.
(04/09/2022 tarihinde https://www.uptodate.com/contents/malignancy-and-rheumaticdisorders?search=paraneoplastik%20sendromlar&source=search_result&selectedTitle=9~150&usage_type=default&display_rank=9 adresinden ulaşılmıştır)
Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocrine-related cancer 2011; 18:R53–R77. doi:10.1530/ERC-11-0006
Naschitz JE, Slobodin G, Yeshurun D, et al. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Archives of internal medicine 1997;157(20):2381.
